Temozolomide

Temozolomide

Clinical data
Routes of administration	Oral
ATC code	L01AX03 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Protein binding	15%
Metabolism	spontaneously hydrolized at physiologic pH to the active species, 3-methyl-(triazen-1-yl)imidazole-4-carboxamide (MTIC) and to temozolomide acid metabolite.
Elimination half-life	1.8 hours
Identifiers
IUPAC name 4-methyl-5-oxo- 2,3,4,6,8-pentazabicyclo [4.3.0] nona-2,7,9-triene- 9-carboxamide
CAS Number	85622-93-1
PubChem CID	5394
DrugBank	APRD00557
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C6H6N6O2
Molar mass	194.151 g/mol

WikiDoc Resources for Temozolomide
Articles
Most recent articles on Temozolomide Most cited articles on Temozolomide Review articles on Temozolomide Articles on Temozolomide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Temozolomide Images of Temozolomide Photos of Temozolomide Podcasts & MP3s on Temozolomide Videos on Temozolomide
Evidence Based Medicine
Cochrane Collaboration on Temozolomide Bandolier on Temozolomide TRIP on Temozolomide
Clinical Trials
Ongoing Trials on Temozolomide at Clinical Trials.gov Trial results on Temozolomide Clinical Trials on Temozolomide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Temozolomide NICE Guidance on Temozolomide NHS PRODIGY Guidance FDA on Temozolomide CDC on Temozolomide
Books
Books on Temozolomide
News
Temozolomide in the news Be alerted to news on Temozolomide News trends on Temozolomide
Commentary
Blogs on Temozolomide
Definitions
Definitions of Temozolomide
Patient Resources / Community
Patient resources on Temozolomide Discussion groups on Temozolomide Patient Handouts on Temozolomide Directions to Hospitals Treating Temozolomide Risk calculators and risk factors for Temozolomide
Healthcare Provider Resources
Symptoms of Temozolomide Causes & Risk Factors for Temozolomide Diagnostic studies for Temozolomide Treatment of Temozolomide
Continuing Medical Education (CME)
CME Programs on Temozolomide
International
Temozolomide en Espanol Temozolomide en Francais
Business
Temozolomide in the Marketplace Patents on Temozolomide
Experimental / Informatics
List of terms related to Temozolomide

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Temozolomide (brand names Temodar and Temodal (Schering-Plough Corporation) is an oral alkylating agent used for the treatment of refractory anaplastic astrocytoma -- a type of cancerous brain tumor. A derivative of imidazotetrazine, temozolomide is the prodrug of MTIC (3-methyl-(triazen-1-yl)imidazole-4-carboxamide). It has been available in the US since August 1999.

Indications

• Anaplastic astrocytoma: for the treatment of adult patients with refractory anaplastic atrocytoma (ie. patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine).
• Unlabeled uses: Metastatic melanoma.

Temozolomide is an imidazotetrazine derivative of the alkylating agent dacarbazine. It undergoes rapid chemical conversion in the systemic circulation at physiological pH to the active compound, MTIC (monomethyl triazeno imidazole carboxamide). Temozolomide exhibits schedule-dependent antineoplastic activity by interfering with DNA replication. Temozolomide has demonstrated activity against recurrent glioma. In a recent randomized trial, concomitant and adjuvant temozolomide chemotherapy with radiation significantly improves progression free survival and overall survival in glioblastoma multiforme patients.

The most common non-hematological adverse effects associated with temozolomide were nausea and vomiting and were either self-limiting or readily controlled with standard antiemetic therapy. These effects were usually mild to moderate (grade 1 to 2). The incidence of severe nausea and vomiting is around 4% each. Patients who have pre-existing or a history of severe vomiting may require antiemetic therapy before initiating temozolomide treatment. Temozolomide should be administered in the fasting state, at least one hour before a meal. Capsules must not be opened or chewed, but are to be swallowed whole with a glass of water. Antiemetic therapy may be administered prior to, or following, administration of temozolomide. Temozolomide is contraindicated in patients with hypersensitivity to its components or to dacarbazine. The use of temozolomide is not recommended in patients with severe myelosuppression. Temozolomide is genotoxic, teratogenic and fetotoxic and should not be used in pregnancy. Nursing should be discontinued while receiving the drug because of the risk of secretion into breast milk. In male patients, temozolomide can have genotoxic effects. Men are advised not to father a child during or up to six months after treatment and to seek advice on cryoconservation of sperm prior to treatment, because of the possibility of irreversible infertility due to temozolomide therapy.

Formulations

Temozolomide is available in the United States in 5mg, 20mg, 100mg, 140mg, 180mg & 250mg capsules.

External links

• Chemotherapy Drug Shrinks Brain Tumors American Academy of Neurology, May 21, 2007